Oncotarget

Research Papers:

ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer

Karineh Petrossian, Noriko Kanaya, Chiao Lo, Pei-Yin Hsu, Duc Nguyen, Lixin Yang, Lu Yang, Charles Warden, Xiwei Wu, Raju Pillai, Lauren Bernal, Chiun-Sheng Huang, Laura Kruper, Yuan Yuan, George Somlo, Joanne Mortimer and Shiuan Chen _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:27736-27751. https://doi.org/10.18632/oncotarget.25552

Metrics: PDF 1206 views  |   HTML 2524 views  |   ?  


Abstract

Karineh Petrossian1, Noriko Kanaya1, Chiao Lo2, Pei-Yin Hsu1, Duc Nguyen1, Lixin Yang3, Lu Yang4, Charles Warden4, Xiwei Wu4, Raju Pillai3, Lauren Bernal1, Chiun-Sheng Huang2, Laura Kruper5, Yuan Yuan6, George Somlo6, Joanne Mortimer6 and Shiuan Chen1

1Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, CA, United States

2Department of Breast Health, National Taiwan University Hospital, Taipei City, Taiwan

3Molecular Pathology Core, Beckman Research Institute of the City of Hope, Duarte, CA, United States

4Integrative Genomics Core, Beckman Research Institute of the City of Hope, Duarte, CA, United States

5Department of Surgery, City of Hope Medical Center, Duarte, CA, United States

6Department of Medical Oncology and Therapeutics Research, City of Hope Medical Center, Duarte, CA, United States

Correspondence to:

Shiuan Chen, email: schen@coh.org

Keywords: CDK4/6 inhibitors; palbociclib; patient-derived xenografts (PDX); single cell analysis; DEPArray

Received: January 04, 2018    Accepted: May 19, 2018    Published: June 12, 2018

ABSTRACT

While ER has multiple biological effects, ER-cyclin D1-CDK4/6-RB is a critical pathway for the action of estrogen on the cell cycle, especially for breast cancers that rely on estrogen for growth. The latest and most efficient CDK4/6 inhibitors target the phosphorylation of retinoblastoma (RB) tumor suppressor gene; thus, altering levels of many cell cycle molecules. Estrogen receptor (ER)+/HER2- breast cancers have shown great progression free survival when CDK4/6 inhibitors are combined with endocrine therapies. Here we report the mechanism of antiestrogen (fulvestrant) combination with CDK4/6 inhibitors is due to synergism in the suppression of ER-mediated cell cycle progression. Furthermore, we performed single cell analysis of cells from an estrogen dependent/hormone receptor-positive patient derived xenograft (PDX) tumor model treated with palbociclib. These single cells expressed various levels of ER and RB which are involved in cell cycle regulation; and the response to palbociclib treatment relies not only on the ER-cyclin D1-CDK4/6-RB pathway but it is also dependent on elevated levels of ER and/or RB. Our preclinical studies show that palbociclib response is dependent on cells with ER, which is directly involved in cell cycle progression in hormone receptor positive (HR+) breast cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25552